Loading
Every dated change on the records linked to Microsatellite-unstable (MSI-high) gastric cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with nivolumab
Untreated unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab
Unresectable or metastatic MSI-high or dMMR colorectal cancer, with ipilimumab
Previously treated MSI-high or dMMR endometrial, biliary, colorectal, gastric or small intestine cancer
Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and does not include pancreatic cancer
OS HR 0.
A milestone in how this cancer is treated.
CPS ≥5: OS 14.
Pembrolizumab alone was non-inferior to chemotherapy for overall survival in PD-L1-positive disease; pembrolizumab plus chemotherapy was not superior to chemotherapy; large benefit in the microsatellite-unstable subgroup.